(PCR) es de gran utilidad. La disponibilidad de

(PCR) es de gran utilidad. La disponibilidad de

Editorial Científico
(PCR) es de gran utilidad. La disponibilidad de antibiogramas
es importante, dadas las altas tasas de resistencia a los fármacos usados normalmente de primera línea.(23) Los actinomicetomas son controlados por la combinación de tratamiento
con antibióticos, sobre todo con sulfonamidas, aminoglucósidos, tetraciclinas o amoxiclavulánico, siendo los carbapenems
y oxazolidinonas prometedoras opciones de tratamiento.(23, 26,
27)
Los eumicetomas se manejan con antimicóticos azólicos,
generalmente en combinación con cirugía.(23, 28)
El Dr. Francisco Kerdel nos instruirá de nuevos tratamientos en Micosis fungoides, donde destacan la fotoféresis extracorpórea,(29) el interferón alfa,(30, 31) bexaroteno,(32)
proteínas de fusión como Ontak®(33) y algunos anticuerpos monoclonales anti CD4 (Zanolimumab),(34) anti CD52
(Alentuzumab®),(35) inhibidores de la histona deacetilasa,(36)
sin olvidar las terapias convencionales.(37)
Quisimos entusiasmarlos con esta parrilla programática.
También contaremos con gratos ambientes, y hemos puesto
especial énfasis en las actividades sociales y en el compartir
experiencias en nuestra gran familia dermatológica. Quedan
todos cordialmente invitados al XXIV Curso Internacional
de Avances en Terapéutica Dermatológica, organizado por
el Departamento de Dermatología de la Universidad de
Chile, los días 26, 27 y 28 de agosto de 2010.
REFERENCIAS BIBLIOGRÁFICAS
1. Doherty SD, Doherty CB, Markus JS, Markus RF. A paradigm for facial skin
rejuvenation. Facial Plast Surg 2009; 25:245-51.
2. Ramos-e-Silva M, da Silva Carneiro SC. Elderly skin and its rejuvenation: products and procedures for the aging skin. J Cosmet Dermatol 2007; 6:40-50.
3. Papadopulos NA, Kovacs L, Krammer S, Herschbach P, Henrich G, Biemer E.
Quality of life following aesthetic plastic surgery: a prospective study. J Plast
Reconstr Aesthet Surg 2007; 60:915-21.
4. Farage MA, Miller KW, Elsner P, Maibach HI. Functional and physiological characteristics of the aging skin. Aging Clin Exp Res 2008; 20:195-200.
5. American Society for Aesthetic Plastic Surgery, Cosmetic Surgery National Data
Bank Statistics for 1997 to 2007. http://www.surgery.org/download/2007stats.
pdf. [Acceso 05-02.08.]
6. Neil S Sadick, MD. The impact of cosmetic interventions on quality of life.
Dermatology Online Journal 2008; 14:2.
7. Gupta MA, Gupta AK, Schork NJ, Ellis CN, Voorhees JJ. The aging face: a
psychocutaneous perspective. J Dermatol Surg Oncol 1990; 16:902-4.
8. Balkrishnan R, McMichael AJ, Hu JY, et al. Correlates of health-related
quality of life in women with severe facial blemishes. Int J Dermatol 2006;
45:111-115.
9. Gupta MA, Schork NJ, Ellis CN. Psychosocial correlates of the treatment of
photodamaged skin with topical retinoic acid: a prospective controlled study.
J Am Acad Dermatol 1994; 30:969-72.
10. Babilas P, Schreml S, Szeimies RM, Landthaler M. Intense pulsed light (IPL): a
review. Lasers Surg Med 2010; 42:93-104.
11. Elsaie ML. Cutaneous remodeling and photorejuvenation using radiofrequency
devices. Indian J Dermatol 2009; 54:201-5.
12. Alexiades-Armenakas M, Rosenberg D, Renton B, Dover J, Arndt K. Blinded,
randomized, quantitative grading comparison of minimally invasive, fractional
radiofrequency and surgical face-lift to treat skin laxity. Arch Dermatol 2010;
146:396-405.
13. Hruza G, Taub AF, Collier SL, Mulholland SR. Skin rejuvenation and wrinkle
reduction using a fractional radiofrequency system. J Drugs Dermatol 2009;
8:259-65.
120
Rev. Chilena Dermatol. 2010; 26(2):118-120
14. Kohl E, Torezan LA, Landthaler M, Szeimies RM. Aesthetic effects of topical
photodynamic therapy. J Eur Acad Dermatol Venereol. 2010 (Mar 5). [Epub
ahead of print]
15. Ruiz-Rodriguez R, López-Rodriguez L. Nonablative skin resurfacing: the role of
PDT. J Drugs Dermatol 2006; 5:756-62.
16. Park MY, Sohn S, Lee ES, Kim YC. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic
analysis. J Am Acad Dermatol 2010; 62:85-95.
17. Bruscino N, Rossi R, Dindelli M, Ghersetich I, Lotti T. Therapeutic Hotline:
Facial skin rejuvenation in a patient treated with photodynamic therapy for
actinic keratosis. Dermatol Ther 2010; 23:86-9.
18. Redaelli A, Romano D, Marciano A. Face and neck revitalization with plateletrich plasma (PRP): clinical outcome in a series of 23 consecutively treated
patients. J Drugs Dermatol 2010; 9:466-72.
19. Kosowski TR, McCarthy C, Reavey PL, Scott AM, Wilkins EG, Cano SJ, Klassen
AF, Carr N, Cordeiro PG, Pusic AL. A systematic review of patient-reported
outcome measures after facial cosmetic surgery and/or nonsurgical facial
rejuvenation. Plast Reconstr Surg 2009; 123:1819-27.
20. Rankin M, Borah GL, Perry AW, Wey PD. Quality-of-life outcomes after cosmetic surgery. Plast Reconstr Surg 1998; 102:2139-2145.
21. Meningaud JP, Benadiba L, Servant JM, Herve C, Bertrand JC, Pelicier Y.
Depression, anxiety and quality of life: outcome 9 months after facial cosmetic
surgery. J Craniomaxillofac Surg 2003; 31:46-50.
22. Ching S, Thoma A, McCabe RE, Antony MM. Measuring outcomes in aesthetic
surgery: a comprehensive review of the literature. Plast Reconstr Surg 2003;
111:469-480.
23. Ameen M, Arenas R. Developments in the management of mycetomas. Clin
Exp Dermatol 2009; 34:1-7.
24. Welsh O, Vera-Cabrera L, Salinas-Carmona MC. Mycetoma. Dermatol Clin
2007; 25: 195-202.
25. Mariat F, Destombes P, Segretain G. The mycetomas: clinical features, pathology, etiology and epidemiology. Contrib Microbiol Immunol 1977; 4:1-39.
26. Mahgoub ES. Treatment of actinomycetoma with sulphamethoxazole plus trimethoprim. Am J Trop Med Hyg 1972; 21:332-5.
27. Joshi R. Treatment of actinomycetoma with combination of rifampicin and cotrimoxazole. Indian J Dermatol Venereol Leprol 2008; 74:166-8.
28. Welsh O, Salinas MC, Rodriguez MA. Treatment of eumycetoma and actinomycetoma. Curr Top Med Mycol 1995; 6:47-71.
29. Smith BD, Wilson LD. Management of mycosis fungoides. Treatment: part 2.
Oncology 2003; 17:1419-28.
30. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol
Ther 2003; 16:311-21.
31. Stadler R, Otte HG, Luger T, Henz BM, Kühl P, ZwingersT, et al. Prospective
randomized multicenter clinical trial on the use of interferon-2a plus acitretin
versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma
stages I and II. Blood 1998; 92:3578-81.
32. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment
of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase
II-III trial results. J Clin Oncol 2001; 19:2456-71.
33. Negro-Vilar A, Dziewanowska Z, Groves ES, Stevens V, Zhang JK, Prince M, et
al. Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind,
placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma
(CTCL). J Clin Oncol 2007; 25 (Suppl):8026.
34. Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C. Zanolimumab,
a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Expert Opin Biol Ther 2008; 8:1929-39.
35. Kennedy GA, Seymour JF, Wolf M, Januszewicz H, Davison J, McCormack C,
et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 2003; 71:250-6.
36. Marchion D, Münster P. Development of histone deacetylase inhibitors for
cancer treatment. Expert Rev Anticancer Ther 2007; 7:583-98.
37. Mestel DS, Beyer M, Steinhoff M, Sterry W. Treatment of cutaneous lymphomas: today and tomorrow. Actas Dermosifiliogr 2009; 100 (Suppl 1):18-32.